A Rao, P Varma, Sumitra, S Dhanya
A Rao, P Varma, Sumitra, S Dhanya. Hyperammonemia: Diagnostic Experience At The Metabolism Laboratory. The Internet Journal of Laboratory Medicine. 2005 Volume 1 Number 2.
Setting: All cases of Hyperammonemia referred to Metabolic Disorders Laboratory, Amrita Institute of Medical Sciences, Kochi from May 2003 were considered.
Ammonia, normally produced from catabolism of amino acids, is a potentially lethal neurotoxin. The conversion of ammonium to urea, which involves urea cycle, occurs in the mitochondrial and cytosolic compartment of hepatocytes. Urea, which contains two nitrogen atoms, is synthesized from aspartate and ammonium mobilized from various sources as detailed above. The urea cycle, also called Krebs-Henseleit cycle, typically involves six enzymatic reactions. The first 3 steps occur in the mitochondria and the next 3 steps occur in the cytoplasm. 1, 2
The concentration of free ammonia in blood is very tightly regulated and is exceeded by two orders of magnitude by its physiologic derivative, urea. The normal capacity for urea production far exceeds the rate of free ammonia production by protein catabolism under normal circumstances, such that any increase in free blood ammonia concentration is a reflection of impairment of urea cycle function or fairly extensive hepatic damage. 1 Clinical signs of hyperammonemia occur at concentrations > 60 micro mol/L and include anorexia, irritability, lethargy, vomiting, somnolence, disorientation, asterixis, cerebral edema, coma, and death; appearance of these findings is generally proportional to free ammonia concentration, is progressive, and is independent of the primary etiology. Common causes of hyperammonemia include genetic defects in the urea cycle, organic acidemias (“secondary urea cycle dysfunction”), as well as genetic or acquired disorders resulting in significant hepatic dysfunction. 2 Hyperammonemia occurs commonly due to defective detoxification in the liver due to a various inborn errors of metabolism and rarely due to excess production in kidneys and intestine. 6 Acute and chronic liver disease resulting in hyperammonemia are also known. Table-1 lists some of the well-recognized causes of hyperammonemia. 2, 3
Enzyme deficiencies of all the five classical urea cycle enzymes result in persistent or episodic hyperammonemia along with accumulation of various intermediates of urea cycle depending on the site of metabolic block. N-acetyl glutamate synthetase deficiency also leads to ammonia accumulation, as N-acetyl glutamate is an allosteric activator of CPS enzyme. 4 The other metabolic disorders affect urea cycle in novel ways. In organic acidemias, the accumulated toxic organic acids and their esters in the mitochondria inhibit CPS-I. Inhibition of N-acetyl glutamate synthetase by propionic acid is another proposed mechanism for hyperammonemia in propionic acidemia. 5 In lysinuric protein
intolerance, defective transport of dibasic amino acids leads to low serum ornithine level (in addition to low lysine and arginine), which is insufficient to support activity of OTC. 6 In hyperammonemia-hyperornithinemia-homocitrullinuria syndrome, intra-mitochondrial ornithine deficiency impairs the activity of OTC. 7 Failure of immediate closure of ductus venosus after birth is thought to result in transient hyperammonemia of newborn as portal blood bypasses the liver. 8 Sodium valproate increases ammonia levels by inhibition of CPS-I enzyme and by activating renal glutaminase activity promoting ammonia formation in kidneys. 9 Addition of topiramate to valproate may increase the propensity to develop hyperammonemia by inhibiting glutamate synthetase in brain. 10 Finally, symptomatic hyperammonemia can also occur in urinary tract infections due to urease producing organisms such as proteus, resynthesising ammonia from urea. 11
We have used High Performance Liquid Chromatography (HPLC, Shimadzu LC 10 AT VP) ) with a Diode array detector (SPD M10 AVP) for quantitations of aminoacids & organic acids. Aminoacids were quantitated using the Phenylisothiocyanate method (PICOTAG) from Waters Corporation. Organic acids were quantitated on the HPLC using a C-18 (150x4.6mm, particle size 5µm) column; mobile phase of 99:1 potassium phosphate buffer (pH 2.5, 50mM): acetonitrile. Flow rate was set of 1.5 ml/minute and detection was at 210nm. All cases of hyperammonemia (> 80 micromole/liter) referred to the Metabolic Disorders Laboratory from May 2003 were evaluated for their aminoacid and organic acid profiles. The distribution of the patients age-wise is shown in Table 2.
Results by summation of all cases are presented in Table-3.
Disorders causing hyperammonemia constitute an important group of potentially treatable metabolic disorders manifesting predominantly with neurological manifestations in early life. Thus, because of the neurotoxic implications of hyperammonemia and the typical absence of other specific laboratory abnormalities, appearance of clinical signs compatible with hyperammonemia should initiate an emergent search for elevated blood ammonia concentration. A value of more than 150 mµol/L (260 µg/dl) in infants and more than 100 µmol/L (175 µg/dl) in older children and adults warrants further biochemical investigations. 3 Though the plasma concentration of ammonia in a symptomatic child is usually 3 or more fold elevated, lower levels can produce symptoms and rarely, raised glutamine alone without hyperammonemia can occur as the biochemical marker of urea cycle dysfunction. After confirming hyperammonemia,
Despite all these investigations, the diagnosis may remain inconclusive especially in patients with episodic symptoms. A re-evaluation during a crisis may possibly yield a diagnosis. We presume the forty-one inconclusive cases are in this category. A genomic / mutation analysis could have probably yielded the diagnosis.
As evident from the data showed, these disorders are not uncommon and they masquerade as common disorders like encephalitis, cerebral palsy and epilepsy. Clinicians should be aware of the various manifestations of these disorders. High index of suspicion and estimation of ammonia levels in appropriate clinical setting is the first step towards the diagnosis. A comprehensive biochemical evaluation should follow to arrive at the final diagnosis.
Though a variety of therapeutic options are available, the developmental outcome is not optimal in majority of cases. Late onset cases with episodic symptoms have better prognosis. Early diagnosis and strict regulation of nitrogen metabolism is crucial in improving the outcome.
We wish to thank Dr. Ahsan Moosa, Amrita Institute of Medical Sciences, Cochin for his contributions in the text & the Departments of Neurology, Pediatrics & Neonatology, Amrita Institute of Medical Sciences, Cochin for their clinical referrals.
Dr.Ananth N Rao, M Chief, Metabolic Disorders Laboratory, Amrita Institute of Medical Sciences, Kochi 682 026 Phone: 0484-5008494 Fax: 0484-2802020 Email: email@example.com